News

Filter

Current filters:

UK

76 to 85 of 96176 results

Allergan says Pershing’s additional requests for meeting is not “meaningful development”

Allergan says Pershing’s additional requests for meeting is not “meaningful development”

15-09-2014

Hostile takeover target Allergan has said that value is what “really matters” in response to Pershing…

AllerganCanadaFinancialLegalPharmaceuticalUSAValeant Pharmaceuticals International

Canadian government commits funding to innovative brain research projects

Canadian government commits funding to innovative brain research projects

15-09-2014

Innovative research projects have been given new funding under the Canada Brain Research Fund, announced…

Brain Canada FoundationCanadaCanada Brain Research FundPharmaceuticalResearch

India’s Dept of Biotech plans financial help for the biotech industry

India’s Dept of Biotech plans financial help for the biotech industry

15-09-2014

Anti-cancer compounds, immunogens against H1N1, cheap recombinant human insulin, stem cell research -…

BiotechnologyFinancialIndiaResearch

FDA approves Baxter/Halozyme’s HyQvia

FDA approves Baxter/Halozyme’s HyQvia

14-09-2014

The US Food and Drug Administration on Friday approved Baxter International’s and Halozyme Therapeutics’…

Baxter InternationalBiotechnologyHalozyme TherapeuticsHyQviaImmunologicalsRegulationUSA

Amarin plunges as FDA denies appeal on ANCHOR trial SPA

Amarin plunges as FDA denies appeal on ANCHOR trial SPA

14-09-2014

Shares of US biotech firm Amarin Corp tanked 23.7% to $1.38 on Friday in heavy trading, when the company…

AmarinCardio-vascularGlaxoSmithKlineLovazaPharmaceuticalRegulationVascepa

Lilly’s Cyramza meets endpoints in Ph III colorectal cancer trial

Lilly’s Cyramza meets endpoints in Ph III colorectal cancer trial

14-09-2014

US pharma major Eli Lilly says that the RAISE trial, a Phase III study of ramucirumab (already marketed…

CyramzaEli LillyOncologyPharmaceuticalResearch

76 to 85 of 96176 results

Company Spotlight

ImmunoGen

ImmunoGen

Back to top